Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region

Francesco Autore, MD, Idanna Innocenti, MD PhD, Francesco Corrente, Maria Ilaria Del Principe, MD, Serena Rosati, MD, Paolo Falcucci, Esmeralda Conte, Maria Assunta Limongiello, Daniela Renzi, Laura De Padua, MD, Alessandro Andriani, MD, Francesco Pisani, MD, Giuseppe Cimino, Agostino Tafuri, MD, Marco Montanaro, MD, Francesca Romana Mauro, Giovanni Del Poeta, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5550.

https://doi.org/10.1182/blood-2018-99-119408

Published: 2018

Journal Articles

Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.

Elisabetta Abruzzese, Massimiliano Postorino, md, phd, Tullio Faraggiana, MD, Daniela Renzi, Manuela Rizzo, Micol Quaresima, Livio Pupo, Roberta Cannarsa, Alessandra Spagnoli, Sara Vaccarini, Malgorzata Monika Trawinska, Lucia Anemona, Giuseppe Lombardo, Maria Cantonetti, MD

Blood (2009) 114 (22): 3717.

https://doi.org/10.1182/blood.V114.22.3717.3717

Published: 2009

Journal Articles

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Paola Panetta, PhD, Daniela Fraboni, PhD, Maria Irno Consalvo, PhD, Daniela Renzi, MD, Selenia Campagna, MD, Chiara Sarlo, MD, Luca Franceschini, MD, Laura Giannì, MD, Emanuele Ammatuna, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2007) 110 (11): 4242.

https://doi.org/10.1182/blood.V110.11.4242.4242

Published: 2007

Journal Articles

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Francesco Buccisano, MD, Luca Maurillo, MD, Valter Gattei, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Paola Panetta, Phd, Daniela Fraboni, Phd, Maria Irno Consalvo, Phd, Licia Ottaviani, MD, Daniela Renzi, MD, Sabrina Faccia, MD, Chiara Sarlo, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2006) 108 (11): 2299.

https://doi.org/10.1182/blood.V108.11.2299.2299

Published: 2006

NARROW

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region

Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region

Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.

Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML.

Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only